Pablo Cagnoni
Director, Sail

Pablo J. Cagnoni, M.D., is President and Head of Research & Development at Incyte where he oversees Incyte’s research and development efforts across its portfolio of programs in Oncology, Hematology and Inflammation and Autoimmunity, including Dermatology.
Prior to Incyte, Dr. Cagnoni served as the Chief Executive Officer of Laronde, a company dedicated to the development of a new type of translatable ribonucleic acid (RNA) called endless RNA (eRNA), and held leadership roles at Rubius Therapeutics, Tizona Therapeutics, Onyx Pharmaceuticals and Novartis Oncology. Throughout his career as a pharmaceutical executive and oncologist, Dr. Cagnoni has advanced the development of breakthrough treatments, playing a key role in the development, approval and commercialization of more than 20 life-changing medicines.
Dr. Cagnoni earned his medical degree from the University of Buenos Aires School of Medicine. He completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York, and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
As well as serving on the Board of Sail, Pablo is a member of the Board of Directors for Fusion Pharmaceuticals and Synthekine. He also serves on the Board of Trustees for the Bay Area Discovery Museum and is a member of the Council on Foreign Relations. He previously served as a board member for CRISPR Therapeutics, Harpoon Therapeutics, Tizona Therapeutics and Tango Therapeutics.
